Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000037040 | SCV000060696 | uncertain significance | not specified | 2013-02-02 | criteria provided, single submitter | clinical testing | The Arg1102Trp variant in MYH14 has not been reported in the literature nor prev iously identified by our laboratory. Computational analyses (biochemical amino a cid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) do not provide str ong support for or against an impact to the protein. Additional data is needed t o determine the clinical significance of this variant. |
Fulgent Genetics, |
RCV002477089 | SCV002777764 | uncertain significance | Autosomal dominant nonsyndromic hearing loss 4A; Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome | 2022-03-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002513455 | SCV003298567 | likely benign | not provided | 2024-10-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004955267 | SCV005453534 | uncertain significance | Inborn genetic diseases | 2024-11-21 | criteria provided, single submitter | clinical testing | The c.3181C>T (p.R1061W) alteration is located in exon 25 (coding exon 24) of the MYH14 gene. This alteration results from a C to T substitution at nucleotide position 3181, causing the arginine (R) at amino acid position 1061 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |